Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 29 050 KRW -0.34% Market Closed
Market Cap: 2T KRW
Have any thoughts about
Hanmi Science Co Ltd?
Write Note

Operating Margin
Hanmi Science Co Ltd

3.5%
Current
3%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.5%
=
Operating Profit
44.3B
/
Revenue
1.3T

Operating Margin Across Competitors

Country KR
Market Cap 2T KRW
Operating Margin
3%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Hanmi Science Co Ltd
Glance View

Market Cap
2T KRW
Industry
Pharmaceuticals

Hanmi Science Co Ltd, rooted in the vibrant economic landscape of South Korea, charts a compelling narrative of innovation and strategic positioning in the pharmaceutical industry. This company, established in the mid-1960s, has evolved into a pivotal player by capitalizing on its robust research and development initiatives. It operates primarily through its subsidiary, Hanmi Pharmaceutical, leveraging cutting-edge biotechnology to engineer novel drug formulations. Their core business model rests on leveraging proprietary technologies to transition new chemical entities from the lab to the market, focusing on niche therapeutic areas such as oncology, diabetes, and autoimmune diseases. By pursuing an aggressive patent strategy, Hanmi Science not only underscores its commitment to innovation but also fortifies its revenue streams by licensing these patented technologies to global pharmaceutical heavyweights. Revenue generation for Hanmi Science is intrinsically tied to its capacity to scale its biotech advances. The company's income flows primarily from licensing agreements, where its patented drug technologies are adopted by international partners, bringing in a steady stream of licensing fees and milestone payments. Additionally, Hanmi selectively engages in product distribution across multiple international markets, further diversifying its revenue base. This strategic mix of monetary inflow via direct product sales and licensing agreements allows Hanmi Science to reinvest substantial portions back into research and development, fueling a cycle of continuous innovation and market competitiveness. Through this dynamic model, Hanmi Science dexterously navigates the complexities of the pharmaceutical landscape, cementing its status as an innovator and a reliable partner in global health advancements.

Intrinsic Value
26 451.35 KRW
Overvaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.5%
=
Operating Profit
44.3B
/
Revenue
1.3T
What is the Operating Margin of Hanmi Science Co Ltd?

Based on Hanmi Science Co Ltd's most recent financial statements, the company has Operating Margin of 3.5%.